文献速递呼吸衰竭与机械通气心脑血管急症

单吸入器三联疗法与长效β2受体激动剂-吸入糖皮质激素治疗COPD:真实世界临床实践中的比较安全性

Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD: Comparative Safety in Real-World Clinical Practice.
PubMed 文献 · Chest · 2024-10-24
一句话结论真实世界COPD患者中,启动单吸入器三联疗法者1年内主要不良心血管事件发生率高于LABA-ICS使用者(HR 1.28,95%CI 1.05-1.55),增加主要来自全因死亡且集中在治疗启动后前4个月。

本研究利用英国临床实践研究数据链(2017-2021年)≥40岁COPD患者队列,在LAMA初治患者中按时间条件倾向评分1:1匹配单吸入器三联疗法启动者与LABA-ICS使用者,各10255例,比较1年内主要不良心血管事件(心肌梗死或卒中住院或全因死亡)。三联疗法MACE发生率为11.3/100人年,LABA-ICS为8.8/100人年,校正HR 1.28(95%CI 1.05-1.55),增加主要在前4个月(HR 1.41,95%CI 1.14-1.74)。全因死亡HR 1.31(95%CI 1.06-1.62),急性心肌梗死住院HR 1.00(95%CI 0.56-1.79),卒中住院HR 1.06(95%CI 0.48-2.36)。作者认为真实世界COPD治疗中启动单吸入器三联疗法者MACE发生率较LABA-ICS相似患者升高,该小幅增加由全因死亡组分驱动,主要发生在治疗启动后前4个月。

要点

  • LAMA初治COPD患者启动单吸入器三联疗法 vs LABA-ICS:1年MACE发生率11.3/100人年 vs 8.8/100人年,校正HR 1.28(95%CI 1.05-1.55)。
  • MACE增加主要发生在治疗启动后前4个月:HR 1.41(95%CI 1.14-1.74)。
  • 全因死亡HR 1.31(95%CI 1.06-1.62),而急性心肌梗死住院HR 1.00(95%CI 0.56-1.79)、卒中住院HR 1.06(95%CI 0.48-2.36),均未达统计学显著。
  • 背景:近期COPD治疗指南已用含LAMA的单吸入器三联疗法替代LABA-ICS联合,但相应试验报告三联疗法心血管不良事件发生率数值上高于LABA-ICS。

适用人群与场景

  • 年龄≥40岁、2017-2021年间在英国临床实践研究数据链中治疗的COPD患者。
  • 分析限于LAMA初治患者,即启动单吸入器三联疗法或使用LABA-ICS者。

研究设计与关键结果

  • 研究类型:基于英国临床实践研究数据链(2017-2021年)的队列研究;LAMA初治的COPD患者中,单吸入器三联疗法启动者按时间条件倾向评分1:1匹配LABA-ICS使用者。
  • 样本量:三联疗法启动者10255例,匹配的LABA-ICS使用者10255例。
  • 主要终点:1年内主要不良心血管事件(MACE,定义为心肌梗死或卒中住院或全因死亡);三联疗法MACE发生率11.3/100人年 vs LABA-ICS 8.8/100人年,校正HR 1.28(95%CI 1.05-1.55)。
  • 时间分层:MACE增加主要在前4个月,HR 1.41(95%CI 1.14-1.74)。
  • 次要终点:全因死亡HR 1.31(95%CI 1.06-1.62);急性心肌梗死住院HR 1.00(95%CI 0.56-1.79);卒中住院HR 1.06(95%CI 0.48-2.36)。

证据类型、等级与局限

  • 证据类型:真实世界队列研究(基于英国临床实践研究数据链的匹配队列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在真实世界COPD治疗中,启动单吸入器三联疗法的患者较接受LABA-ICS吸入器的相似患者MACE发生率升高,该小幅增加由全因死亡组分驱动,主要发生在治疗启动后前4个月。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent treatment guidelines for COPD have replaced the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA). However, the corresponding trials reported numerically higher incidences of cardiovascular adverse events with triple therapy compared with LABA-ICS.

RESEARCH QUESTION: Does single-inhaler triple therapy increase the incidence of major adverse cardiovascular events, compared with LABA-ICS, in a real-world clinical practice setting?

STUDY DESIGN AND METHODS: We identified a cohort of patients with COPD aged ≥ 40 years treated during 2017-2021 from the UK's Clinical Practice Research Datalink. Among LAMA-naive patients, initiators of single-inhaler triple therapy were matched 1:1 to LABA-ICS users on time-conditional propensity scores. They were compared on the incidence of major adverse cardiovascular events (MACEs), defined as hospitalization for myocardial infarction or stroke, or all-cause-mortality, over 1 year.

RESULTS: The cohort included 10,255 initiators of triple therapy and 10,255 matched users of LABA-ICS. The incidence rate of MACEs was 11.3 per 100 per year with triple therapy compared with 8.8 per 100 per year for LABA-ICS. The corresponding adjusted hazard ratio (HR) of MACEs with triple therapy was 1.28 (95% CI, 1.05-1.55), relative to LABA-ICS; however, the increase was mainly in the first 4 months (HR, 1.41; 95% CI, 1.14-1.74). The HR of all-cause death was 1.31 (95% CI, 1.06-1.62), whereas for acute myocardial infarction and stroke hospitalization it was 1.00 (95% CI, 0.56-1.79) and 1.06 (95% CI, 0.48-2.36), respectively, with triple therapy, relative to LABA-ICS.

INTERPRETATION: In a real-world setting of COPD treatment, patients who initiated single-inhaler triple therapy had an increased incidence of MACEs compared with similar patients treated with an LABA-ICS inhaler. This small increase was due to the all-cause mortality component, occurring mainly in the first 4 months after treatment initiation.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Suissa S, Dell'Aniello S, Ernst P, et al. Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD: Comparative Safety in Real-World Clinical Practice. Chest. 2024. PMID: 39461554. doi:10.1016/j.chest.2024.10.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。